{
    "clinical_study": {
        "@rank": "65480", 
        "arm_group": [
            {
                "arm_group_label": "Adult Fluzone\u00ae Quadrivalent Influenza Vaccine (Group 1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants age 18 to < 65 years randomized to receive a dose of Fluzone\u00ae Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)"
            }, 
            {
                "arm_group_label": "Adult Fluzone\u00ae Intradermal Influenza Vaccine (Group 2)", 
                "arm_group_type": "Experimental", 
                "description": "Participants age 18 to < 65 years randomized to receive a dose of Fluzone Intradermal Influenza Virus Vaccine (2013-2014 formulation)"
            }, 
            {
                "arm_group_label": "Elderly Fluzone\u00ae Quadrivalent Influenza Vaccine (Group 3)", 
                "arm_group_type": "Experimental", 
                "description": "Participants age \u2265 65 years randomized to receive a dose of Fluzone\u00ae Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)"
            }, 
            {
                "arm_group_label": "Elderly Fluzone\u00ae High Dose Influenza Vaccine (Group 4)", 
                "arm_group_type": "Experimental", 
                "description": "Participants age \u2265 65 years randomized to receive a dose of Fluzone\u00ae High Dose Influenza Virus Vaccine (2013-2014 formulation)"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is describe the safety and immunogenicity of Fluzone Quadrivalent and\n      Fluzone Intradermal vaccines in adults 18 to < 65 years of age, and to describe the safety\n      and immunogenicity of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults \u2265 65\n      years of age.\n\n      Primary Objective:\n\n        -  To describe the safety of the 2013-2014 formulations of Fluzone Quadrivalent and\n           Fluzone Intradermal vaccines in adults 18 to < 65 years of age and the safety of the\n           2013-2014 formulations of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults\n           \u2265 65 years of age.\n\n      Observational objectives:\n\n        -  To describe the immunogenicity of the 2013-2014 formulations of Fluzone Quadrivalent\n           and Fluzone Intradermal vaccines in adults 18 to < 65 years of age and the\n           immunogenicity of the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone\n           High-Dose vaccines in adults \u2265 65 years of age.\n\n        -  To evaluate the compliance, in terms of immunogenicity, of each study vaccine (Fluzone\n           Quadrivalent, Fluzone Intradermal, and Fluzone High-Dose) in the applicable age group\n           with the requirements of the Committee for Human Medicinal Products (CHMP) Note for\n           Guidance (NfG) CPMP/BWP/214/96.\n\n        -  To submit sera from selected subjects to the Center for Biologics Evaluation and\n           Research (CBER) for further analysis by the World Health Organization (WHO), the\n           Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration\n           (FDA) to support formulation recommendations for subsequent influenza vaccines."
        }, 
        "brief_title": "Study of Fluzone\u00ae Quadrivalent, Fluzone\u00ae Intradermal, and Fluzone\u00ae High-Dose Influenza Virus Vaccines in Adults", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "Participants 18 to < 65 years of age on enrollment will be randomized to receive either\n      Fluzone Quadrivalent or Fluzone Intradermal vaccine. Participants \u2265 65 years of age at\n      enrollment will be randomized to receive either Fluzone Quadrivalent or Fluzone High-Dose\n      vaccine.\n\n      Solicited adverse event (AE) information will be collected for 7 days after each\n      vaccination, unsolicited AE and Serious adverse event information will be collected from\n      Visit 1 to Visit 2. Total duration of participation in the study is approximately 21 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is \u2265 18 years of age on the day of inclusion\n\n          -  Informed consent form has been signed and dated\n\n          -  Able to attend all scheduled visits and to comply with all trial procedures.\n\n        Exclusion Criteria:\n\n          -  History of serious adverse reaction to any influenza vaccine\n\n          -  Receipt of any vaccine within 30 days before receiving study vaccine, or plans to\n             receive another vaccine before Visit 2.\n\n          -  Participation in another interventional clinical trial investigating a vaccine, drug,\n             medical device, or medical procedure in the 30 days preceding the first study\n             vaccination or during the course of the study, unless no intervention for the other\n             study occurred within the 30 days prior to the first study vaccination and none are\n             planned before the subject would complete safety surveillance for the present study\n\n          -  Thrombocytopenia, which may be a contraindication for intramuscular vaccination, at\n             the discretion of the Investigator\n\n          -  Prior vaccination with any 2013-2014 formulation of influenza vaccine\n\n          -  Known systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine\n             components, or a history of a life-threatening reaction to Fluzone Quadrivalent,\n             Fluzone Intradermal, or Fluzone High-Dose vaccine or to a vaccine containing any of\n             the same substances (the complete list of vaccine components is included in the\n             Prescribing Information)\n\n          -  Receipt of immune globulins, blood, or blood-derived products in the past 3 months\n\n          -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             which may be a contraindication for intramuscular vaccination, at the discretion of\n             the Investigator\n\n          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of\n             non-childbearing potential, a female must be pre-menarche or post-menopausal for at\n             least 1 year, surgically sterile, or using an effective method of contraception or\n             abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks\n             after vaccination)\n\n          -  Any condition that in the opinion of the Investigator would pose a health risk to the\n             subject if enrolled or could interfere with the evaluation of the vaccine\n\n          -  Personal history of Guillain-Barr\u00e9 syndrome\n\n          -  Known or suspected congenital or acquired immunodeficiency; or receipt of\n             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,\n             within the preceding 6 months; or long-term systemic corticosteroid therapy\n             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n\n          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it\n             might interfere with trial conduct or completion\n\n          -  Seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C,\n             as reported by the subject\n\n          -  Deprived of freedom by an administrative or court order, or in an emergency setting,\n             or hospitalized involuntarily\n\n          -  Current alcohol or drug addiction that, in the opinion of the Investigator, might\n             interfere with the ability to comply with trial procedures\n\n          -  Moderate or severe acute illness/infection (according to Investigator judgment) or\n             febrile illness (temperature \u2265 100.4\u00b0F]) on the day of vaccination. A prospective\n             subject should not be included in the study until the condition has resolved or the\n             febrile event has subsided\n\n          -  Identified as an Investigator or employee of the Investigator or study center with\n             direct involvement in the proposed study, or identified as an immediate family member\n             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with\n             direct involvement in the proposed study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "208", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946438", 
            "org_study_id": "GRC52", 
            "secondary_id": "U1111-1127-7587"
        }, 
        "intervention": [
            {
                "arm_group_label": "Adult Fluzone\u00ae Quadrivalent Influenza Vaccine (Group 1)", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "Fluzone\u00ae Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone\u00ae Quadrivalent, Influenza Virus Vaccine"
            }, 
            {
                "arm_group_label": "Adult Fluzone\u00ae Intradermal Influenza Vaccine (Group 2)", 
                "description": "0.1 mL, Intradermal", 
                "intervention_name": "Fluzone\u00ae Intradermal Influenza Virus Vaccine (2013-2014 formulation),", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone\u00ae Intradermal Influenza Virus Vaccine"
            }, 
            {
                "arm_group_label": "Elderly Fluzone\u00ae Quadrivalent Influenza Vaccine (Group 3)", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "Fluzone\u00ae Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone\u00ae Quadrivalent, Influenza Virus Vaccine"
            }, 
            {
                "arm_group_label": "Elderly Fluzone\u00ae High Dose Influenza Vaccine (Group 4)", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "Fluzone\u00ae High Dose Influenza Virus Vaccine (2013-2014 formulation)", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone\u00ae High Dose Influenza Virus Vaccine"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Influenza", 
            "Fluzone\u00ae Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),", 
            "Fluzone\u00ae Intradermal, Influenza Virus Vaccine (2013-2014 formulation),", 
            "Fluzone\u00ae High-Dose, Influenza Virus Vaccine (2013-2014 formulation)"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santa Rosa, CA 95405", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95405"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Council Bluffs", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "51503"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70006"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45249"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety and Immunogenicity Among Adults of Fluzone\u00ae Quadrivalent, Fluzone\u00ae Intradermal, and Fluzone\u00ae High-Dose Influenza Virus Vaccines, 2013-2014 Formulations", 
        "overall_official": {
            "affiliation": "Sanofi Pasteur Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Solicited injection site reactions: Pain, Redness, Swelling, Induration, and Ecchymosis. Solicited systemic reactions:  Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Unsolicited adverse events including serious adverse events will also be collected.", 
            "measure": "Number of participants reporting solicited injection site and systemic events and unsolicited adverse events following vaccination with Fluzone\u00ae influenza virus vaccines", 
            "safety_issue": "No", 
            "time_frame": "Day 0 up to 21 Days post vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946438"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) and seroprotection and seroconversion will be calculated.", 
                "measure": "Geometric mean titers of antibodies to vaccine antigens following vaccination with Fluzone\u00ae Quadrivalent, or Fluzone Intradermal, or Fluzone High Dose vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 21 post vaccination"
            }, 
            {
                "description": "Seroprotection is defined as a titer \u2265 40 (l/dil) at pre vaccination and at 21days after vaccination. Seroconversion is defined as: Either a pre vaccination titer < 10 (1/dil) and a post vaccination titer \u2265 40 (1/dil), or a pre vaccination titer \u2265 10 (1/dil) and a \u2265 4 fold increase in post vaccination titer at 21 days after vaccination", 
                "measure": "Seroprotection and seroconversion to vaccine antigens following vaccination with Fluzone\u00ae influenza virus vaccines", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 21 post vaccination"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}